Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03929159 · ClinicalTrials.gov registry record

Correlating MicroRNA Changes With Sepsis Outcomes

A clinical trial of Septicemia, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
150
Enrollment target
1
Study location

NCT03929159 is a study of Septicemia that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 150 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03929159, a study of Septicemia, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

This trial studies how changes in microRNAs may correlate with sepsis outcomes. Sepsis is a type of severe infection of the blood stream, and its diagnosis may be obscured by many other conditions such as surgery, trauma, and cancer. MicroRNAs are biomarkers found in the blood and tissue. Blood samples may help correlate changes in microRNA expression to patient reactions to a sepsis infection.

Conditions Studied

Interventions

  • PROCEDURE Biospecimen Collection

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2019-03-26
Est. Completion 2026-12-31

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT03929159

The ClinicalTrials.gov registry entry for NCT03929159 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Septicemia appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen Collection is the first listed.

NCT03929159 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03929159 about?

NCT03929159 is a clinical study titled "Correlating MicroRNA Changes With Sepsis Outcomes". This trial studies how changes in microRNAs may correlate with sepsis outcomes. Sepsis is a type of severe infection of the blood stream, and its diagnosis may be obscured by many other conditions such as surgery, trauma, and cancer. MicroRNAs are biomarkers found in the blood and tissue. Blood samp...

What is the current status of trial NCT03929159?

This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2019-03-26. Estimated completion is 2026-12-31.

What conditions does trial NCT03929159 study?

This clinical trial studies the following conditions: Septicemia.

What interventions are being tested in trial NCT03929159?

The interventions under investigation include: Biospecimen Collection (PROCEDURE).

Who is sponsoring clinical trial NCT03929159?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03929159 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Septicemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.